Given that in murine T cells SPHK inhibition and/or ablation improves T cell mediated tumor control against murine melanoma and increases the secretion of an array of cytokines in response to stimulation, further experiments are warranted to evaluate whether this is also the case in T cells of CLL patients (37–39). This evidence concerns the gene SPHK1 and B-cell chronic lymphocytic leukemia.